Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Unger

Showing results (331-340 of 503) with videos related to

Pageof 51
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 19, 2013
A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213S H Bernstein, E Epner, J M Unger, et al.
International Immunology|February 18, 1998
Bet v 1, the major birch pollen allergen, conjugated to crystalline bacterial cell surface proteins, expands allergen-specific T cells of the Th1/Th0 phenotype in vitro by induction of IL-12B Jahn-Schmid, U Siemann, A Zenker, et al.
Investigational New Drugs|September 20, 2001
Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy. A Southwest Oncology Group studyR P Whitehead, J M Unger, L E Flaherty, et al.
Journal of the National Cancer Institute|March 14, 2018
Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention TrialJoseph M Unger, Dawn L Hershman, Cathee Till, et al.
Molecular Cancer Therapeutics|May 29, 2014
Mechanism and efficacy of sub-50-nm tenfibgen nanocapsules for cancer cell-directed delivery of anti-CK2 RNAi to primary and metastatic squamous cell carcinomaGretchen M Unger, Betsy T Kren, Vicci L Korman, et al.
Journal of the National Cancer Institute. Monographs|February 24, 2025
When to adjust for multiplicity in cancer clinical trialsJoseph M Unger, Gina L Mazza, Mohamed I Elsaid, et al.
Osteoarthritis and Cartilage|October 6, 2009
Phenotype-related differential alpha-2,6- or alpha-2,3-sialylation of glycoprotein N-glycans in human chondrocytesS Toegel, M Pabst, S Q Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2009
Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897Dawn L Hershman, Joseph M Unger, William E Barlow, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 22, 2003
The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trialPatrick J Stiff, Joseph M Unger, Stephen J Forman, et al.
The Journal of Clinical Investigation|June 11, 2009
Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A miceBetsy T Kren, Gretchen M Unger, Lucas Sjeklocha, et al.
Pageof 51

Showing results (331-340 of 503) with videos related to

Sort By:
Pageof 51
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 19, 2013
A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213S H Bernstein, E Epner, J M Unger, et al.
International Immunology|February 18, 1998
Bet v 1, the major birch pollen allergen, conjugated to crystalline bacterial cell surface proteins, expands allergen-specific T cells of the Th1/Th0 phenotype in vitro by induction of IL-12B Jahn-Schmid, U Siemann, A Zenker, et al.
Investigational New Drugs|September 20, 2001
Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy. A Southwest Oncology Group studyR P Whitehead, J M Unger, L E Flaherty, et al.
Journal of the National Cancer Institute|March 14, 2018
Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention TrialJoseph M Unger, Dawn L Hershman, Cathee Till, et al.
Molecular Cancer Therapeutics|May 29, 2014
Mechanism and efficacy of sub-50-nm tenfibgen nanocapsules for cancer cell-directed delivery of anti-CK2 RNAi to primary and metastatic squamous cell carcinomaGretchen M Unger, Betsy T Kren, Vicci L Korman, et al.
Journal of the National Cancer Institute. Monographs|February 24, 2025
When to adjust for multiplicity in cancer clinical trialsJoseph M Unger, Gina L Mazza, Mohamed I Elsaid, et al.
Osteoarthritis and Cartilage|October 6, 2009
Phenotype-related differential alpha-2,6- or alpha-2,3-sialylation of glycoprotein N-glycans in human chondrocytesS Toegel, M Pabst, S Q Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2009
Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897Dawn L Hershman, Joseph M Unger, William E Barlow, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 22, 2003
The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trialPatrick J Stiff, Joseph M Unger, Stephen J Forman, et al.
The Journal of Clinical Investigation|June 11, 2009
Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A miceBetsy T Kren, Gretchen M Unger, Lucas Sjeklocha, et al.
Pageof 51